Parkinson's disease (PD) is a neurodegenerative condition characterized by chronic inflammation. Nuclear factor B (NF- B) is a family of inducible transcription factors that are expressed in a wide variety of cells and tissues, including microglia, astrocytes, and neurons, and the classical NF- B pathway plays a key role in the activation and regulation of inflammatory mediator production during inflammation. Activation of the classical NF- B pathway is mediated through the activity of the IKK kinase complex, which consists of a heterotrimer of IKK , IKK , and IKK subunits. Targeting NF- B has been proposed as an approach to the treatment of acute and chronic inflammatory conditions, and the use of inhibitors specific for either IKK or IKK has now been found to inhibit neurodegeneration of TH+ DA-producing neurons in murine and primate models of Parkinson's disease. These studies suggest that targeting the classical pathway of NF- B through the inhibition of the IKK complex can serve as a useful therapeutic approach to the treatment of PD. 1. Introduction Parkinson's disease (PD) is a progressive degenerative disorder of the central nervous system (CNS) that leads to impairment of motor skills and speech, as well as other functions. While the disease mechanisms that ultimately cause PD are still unclear, it is believed that the progressive nature of PD is characterized by chronic inflammation-induced neurodegeneration of dopamine-producing neurons within the substantia nigra (SN) and striatum [1–4]. It is now well documented that microglial activation results in the loss of dopaminergic neurons (DA-neurons). The premise of microglia activation in PD has been supported by analysis of postmortem brains from PD patients, which provides clear evidence of microglia activation in the SN. In the brains of patients with PD, large numbers of human leukocyte antigen (HLA-DR) and CD11b-positive reactive microglia were found in the SN, a region in which the degeneration of DA-neurons was most prominent [5–8]. In addition, levels of proinflammatory mediators, including TNFα, IL-1β, IL-6, and eicosanoids are elevated in the brains and peripheral blood mononuclear cells (PBMCs) of patients with PD [6, 7]. Nitrite in the cerebrospinal fluid as well as increased expression of inducible nitric oxide synthase (iNOS) within the SN have been found in PD patients [9, 10]. All of these findings lend strong support to the association of inflammation and PD. Many of these inflammatory mediators have been demonstrated to have strong neurotoxic effects on DA-neurons [1, 11–14],
References
[1]
M. L. Block and J. S. Hong, “Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism,” Progress in Neurobiology, vol. 76, no. 2, pp. 77–98, 2005.
[2]
A. L. Bartels and K. L. Leenders, “Neuroinflammation in the pathophysiology of Parkinson's disease: evidence from animal models to human in vivo studies with [C]-PK11195 PET,” Movement Disorders, vol. 22, no. 13, pp. 1852–1856, 2007.
[3]
W. Dauer and S. Przedborski, “Parkinson's disease: mechanisms and models,” Neuron, vol. 39, no. 6, pp. 889–909, 2003.
[4]
H. M. Gao and J. S. Hong, “Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression,” Trends in Immunology, vol. 29, no. 8, pp. 357–365, 2008.
[5]
P. L. McGeer, S. Itagaki, B. E. Boyes, and E. G. McGeer, “Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains,” Neurology, vol. 38, no. 8, pp. 1285–1291, 1988.
[6]
T. Nagatsu, M. Mogi, H. Ichinose, and A. Togari, “Changes in cytokines and neurotrophins in Parkinson's disease,” Journal of Neural Transmission, no. 60, supplement, pp. 277–290, 2000.
[7]
M. Mogi, M. Harada, T. Kondob et al., “Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients,” Neuroscience Letters, vol. 180, no. 2, pp. 147–150, 1994.
[8]
Y. Ouchi, S. Yagi, M. Yokokura, and M. Sakamoto, “Neuroinflammation in the living brain of Parkinson's disease,” Parkinsonism and Related Disorders, vol. 15, no. 3, pp. S200–S204, 2009.
[9]
G. A. Qureshi, S. Baig, I. Bednar, P. Sodersten, G. Forsberg, and A. Siden, “Increased cerebrospinal fluid concentration of nitrite ire Parkinson's disease,” NeuroReport, vol. 6, no. 12, pp. 1642–1644, 1995.
[10]
S. Hunot, F. Boissière, B. Faucheux et al., “Nitric oxide synthase and neuronal vulnerability in Parkinson's disease,” Neuroscience, vol. 72, no. 2, pp. 355–363, 1996.
[11]
L. Qian and P. M. Flood, “Microglial cells and Parkinson's disease,” Immunologic Research, vol. 41, no. 3, pp. 155–164, 2008.
[12]
M. K. McCoy and M. G. Tansey, “TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease,” Journal of Neuroinflammation, vol. 5, article 45, 2008.
[13]
P. Jenner, “Oxidative mechanisms in nigral cell death in Parkinson's disease,” Movement Disorders, vol. 13, supplement 1, pp. 24–34, 1998.
[14]
J. Zielasek and H. P. Hartung, “Molecular mechanisms of microglial activation,” Advances in Neuroimmunology, vol. 6, no. 2, pp. 191–222, 1996.
[15]
J. Rogers and L. F. Lue, “Microglial chemotaxis, activation, and phagocytosis of amyloid β-peptide as linked phenomena in Alzheimer's disease,” Neurochemistry International, vol. 39, no. 5-6, pp. 333–340, 2001.
[16]
T. C. Frank-Cannon, T. Tran, K. A. Ruhn et al., “Parkin deficiency increases vulnerability to inflammation-related nigral degeneration,” Journal of Neuroscience, vol. 28, no. 43, pp. 10825–10834, 2008.
[17]
A. D. Reynolds, J. G. Glanzer, I. Kadiu et al., “Nitrated alpha-synuclein-activated microglial profiling for Parkinson's disease,” Journal of Neurochemistry, vol. 104, no. 6, pp. 1504–1525, 2008.
[18]
E. C. Hirsch, S. Hunot, and A. Hartmann, “Neuroinflammatory processes in Parkinson's disease,” Parkinsonism and Related Disorders, vol. 11, no. 1, pp. S9–S15, 2005.
[19]
H. Wilms, L. Zecca, P. Rosenstiel, J. Sievers, G. Deuschl, and R. Lucius, “Inflammation in Parkinson's diseases and other neurodegenerative diseases: cause and therapeutic implications,” Current Pharmaceutical Design, vol. 13, no. 18, pp. 1925–1928, 2007.
[20]
P. L. McGeer, C. Schwab, A. Parent, and D. Doudet, “Presence of reactive microglia in monkey Substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration,” Annals of Neurology, vol. 54, no. 5, pp. 599–604, 2003.
[21]
F. Cicchetti, A. L. Brownell, K. Williams, Y. I. Chen, E. Livni, and O. Isacson, “Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging,” European Journal of Neuroscience, vol. 15, no. 6, pp. 991–998, 2002.
[22]
W. Meissner, C. Prunier, D. Guilloteau, S. Chalon, C. E. Gross, and E. Bezard, “Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease,” Molecular Neurobiology, vol. 28, no. 3, pp. 209–218, 2003.
[23]
A. D. Ebert, J. H. Hoo, and M. C. Bohn, “Progressive degeneration of dopamine neurons in 6-hydroxydopamine rat model of Parkinson's disease does not involve activation of caspase-9 and caspase-3,” Journal of Neuroscience Research, vol. 86, no. 2, pp. 317–325, 2008.
[24]
A. R. Simard and S. Rivest, “Do pathogen exposure and innate immunity cause brain diseases?” Neurological Research, vol. 27, no. 7, pp. 717–725, 2005.
[25]
R. M. Ransohoff and V. H. Perry, “Microglial physiology: unique stimuli, specialized responses,” Annual Review of Immunology, vol. 27, pp. 119–145, 2009.
[26]
G. C. Brown and J. J. Neher, “Inflammatory neurodegeneration and mechanisms of microglial killing of neurons,” Molecular Neurobiology, vol. 41, no. 2-3, pp. 242–247, 2010.
[27]
M. Mogi, M. Harada, P. Riederer, H. Narabayashi, K. Fujita, and T. Nagatsu, “Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients,” Neuroscience Letters, vol. 165, no. 1-2, pp. 208–210, 1994.
[28]
H. Arai, T. Furuya, T. Yasuda, M. Miura, Y. Mizuno, and H. Mochizuki, “Neurotoxic effects of lipopolysaccharide on nigral dopaminergic neurons are mediated by microglial activation, interleukin-1β, and expression of caspase-11 in mice,” Journal of Biological Chemistry, vol. 279, no. 49, pp. 51647–51653, 2004.
[29]
W. M. Caudle and J. Zhang, “Glutamate, excitotoxicity, and programmed cell death in parkinson disease,” Experimental Neurology, vol. 220, no. 2, pp. 230–233, 2009.
[30]
D. W. Choi, “Glutamate neurotoxicity and diseases of the nervous system,” Neuron, vol. 1, no. 8, pp. 623–634, 1988.
[31]
L. Thirumangalakudi, L. Yin, H. V. Rao, and P. Grammas, “IL-8 induces expression of matrix metalloproteinases, cell cycle and pro-apoptotic proteins, and cell death in cultured neurons,” Journal of Alzheimer's Disease, vol. 11, no. 3, pp. 305–311, 2007.
[32]
D. A. Loeffler, A. J. DeMaggio, P. L. Juneau, M. K. Havaich, and P. A. LeWitt, “Effects of enhanced striatal dopamine turnover in vivo on glutathione oxidation,” Clinical Neuropharmacology, vol. 17, no. 4, pp. 370–379, 1994.
[33]
K. Imamura, N. Hishikawa, M. Sawada, T. Nagatsu, M. Yoshida, and Y. Hashizume, “Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains,” Acta Neuropathologica, vol. 106, no. 6, pp. 518–526, 2003.
[34]
C. Barcia, V. De Pablos, V. Bautista-Hernández et al., “Increased plasma levels of TNF-α but not of IL1-β in MPTP-treated monkeys one year after the MPTP administration,” Parkinsonism and Related Disorders, vol. 11, no. 7, pp. 435–439, 2005.
[35]
R. Sen and D. Baltimore, “Multiple nuclear factors interact with the immunoglobulin enhancer sequences,” Cell, vol. 46, no. 5, pp. 705–716, 1986.
[36]
R. Sen and D. Baltimore, “Inducibility of K immunoglobulin enhancer-binding protein NF- B by a posttranslational mechanism,” Cell, vol. 47, no. 6, pp. 921–928, 1986.
[37]
G. Tsoulfas and D. A. Geller, “NF-κB in transplantation: friend or foe?” Transplant Infectious Disease, vol. 3, no. 4, pp. 212–219, 2001.
[38]
K. A. Roebuck, “Regulation of interleukin-8 gene expression,” Journal of Interferon and Cytokine Research, vol. 19, no. 5, pp. 429–438, 1999.
[39]
Y. Xia, M. E. Pauza, L. Feng, and D. Lo, “RelB regulation of chemokine expression modulates local inflammation,” American Journal of Pathology, vol. 151, no. 2, pp. 375–387, 1997.
[40]
K. A. Roebuck, L. R. Carpenter, V. Lakshminarayanan, S. M. Page, J. N. Moy, and L. L. Thomas, “Stimulus-specific regulation of chemokine expression involves differential activation of the redox-responsive transcription factors AP-1 and NF-κB,” Journal of Leukocyte Biology, vol. 65, no. 3, pp. 291–298, 1999.
[41]
T. Lawrence, “The nuclear factor NF-kappaB pathway in inflammation,” Cold Spring Harbor Perspectives in Biology, vol. 1, no. 6, article a001651, 2009.
[42]
K. A. Gauss, L. K. Nelson-Overton, D. W. Siemsen, Y. Gao, F. R. DeLeo, and M. T. Quinn, “Role of NF-κB in transcriptional regulation of the phagocyte NADPH oxidase by tumor necrosis factor-α,” Journal of Leukocyte Biology, vol. 82, no. 3, pp. 729–741, 2007.
[43]
C. C. Chen and A. M. Manning, “Transcriptional regulation of endothelial cell adhesion molecules: a dominant role for NF-κB,” Agents and Actions Supplements, vol. 47, pp. 135–141, 1995.
[44]
P. P. Tak and G. S. Firestein, “NF-κB: a key role in inflammatory diseases,” Journal of Clinical Investigation, vol. 107, no. 1, pp. 7–11, 2001.
[45]
K. Van der Heiden, S. Cuhlmann, A. Luong, M. Zakkar, and P. C. Evans, “Role of nuclear factor kappaB in cardiovascular health and disease,” Clinical Science, vol. 118, no. 10, pp. 593–605, 2010.
[46]
C. A. Latanich and L. H. Toledo-Pereyra, “Searching for NF-κB-based treatments of ischemia reperfusion injury,” Journal of Investigative Surgery, vol. 22, no. 4, pp. 301–315, 2009.
[47]
K. Vandenbroeck, I. Alloza, M. Gadina, and P. Matthys, “Inhibiting cytokines of the interleukin-12 family: recent advances and novel challenges,” Journal of Pharmacy and Pharmacology, vol. 56, no. 2, pp. 145–160, 2004.
[48]
L. A. Criswell, “Gene discovery in rheumatoid arthritis highlights the CD40/NF-κB signaling pathway in disease pathogenesis,” Immunological Reviews, vol. 233, no. 1, pp. 55–61, 2010.
[49]
I. Atreya, R. Atreya, and M. F. Neurath, “NF-κB in inflammatory bowel disease,” Journal of Internal Medicine, vol. 263, no. 6, pp. 591–596, 2008.
[50]
T. Lawrence and C. Fong, “The resolution of inflammation: anti-inflammatory roles for NF-κB,” International Journal of Biochemistry and Cell Biology, vol. 42, no. 4, pp. 519–523, 2010.
[51]
S. G. Pereira and F. Oakley, “Nuclear factor-κB1: regulation and function,” International Journal of Biochemistry and Cell Biology, vol. 40, no. 8, pp. 1425–1430, 2008.
[52]
M. S. Wang, S. Boddapati, S. Emadi, and M. R. Sierks, “Curcumin reduces α-synuclein induced cytotoxicity in Parkinson's disease cell model,” BMC Neuroscience, vol. 11, article 57, 2010.
[53]
T. Huxford and G. Ghosh, “A structural guide to proteins of the NF-kappaB signaling module,” Cold Spring Harbor Perspectives in Biology, vol. 1, no. 3, article a000075, 2009.
[54]
A. Oeckinghaus and S. Ghosh, “The NF-kappaB family of transcription factors and its regulation,” Cold Spring Harbor Perspectives in Biology, vol. 1, no. 4, article a000034, 2009.
[55]
M. J. May, R. B. Marienfeld, and S. Ghosh, “Characterization of the IκB-kinase NEMO binding domain,” Journal of Biological Chemistry, vol. 277, no. 48, pp. 45992–46000, 2002.
[56]
N. Sizemore, et al., “Distinct roles of the Ikappa B kinase alpha and beta subunits in liberating nuclear factor kappa B (NF-kappa B) from Ikappa B and in phosphorylating the p65 subunit of NF-kappa B,” The Journal of Biological Chemistry, vol. 277, no. 6, pp. 3863–3869, 2002.
[57]
N. Sizemore, A. Agarwal, K. Das et al., “Inhibitor of κB kinase is required to activate a subset of interferon γ-stimulated genes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 21, pp. 7994–7998, 2004.
[58]
J. Y. Reuther-Madrid, D. Kashatus, S. Chen et al., “The p65/RelA subunit of NF-κB suppresses the sustained, antiapoptotic activity of Jun kinase induced by tumor necrosis factor,” Molecular and Cellular Biology, vol. 22, no. 23, pp. 8175–8183, 2002.
[59]
D. Rudolph, W. C. Yeh, A. Wakeham et al., “Severe liver degeneration and lack of NF-κB activation in NEMO/IKK γ- deficient mice,” Genes and Development, vol. 14, no. 7, pp. 854–862, 2000.
[60]
Z. P. Xia and Z. J. Chen, “TRAF2: a double-edged sword?” Science's STKE, vol. 2005, no. 272, p. e7, 2005.
[61]
M. Neumann and M. Naumann, “Beyond IκBs: alternative regulation of NF-κB activity,” FASEB Journal, vol. 21, no. 11, pp. 2642–2654, 2007.
[62]
K. D. Brown, E. Claudio, and U. Siebenlist, “The roles of the classical and alternative nuclear factor-κB pathways: potential implications for autoimmunity and rheumatoid arthritis,” Arthritis Research and Therapy, vol. 10, no. 4, article 212, 2008.
[63]
A. Israel, “The IKK complex, a central regulator of NF-kappaB activation,” Cold Spring Harbor Perspectives in Biology, vol. 2, no. 3, article a000158, 2010.
[64]
N. Bakkar and D. C. Guttridge, “NF-κB signaling: a tale of two pathways in skeletal myogenesis,” Physiological Reviews, vol. 90, no. 2, pp. 495–511, 2010.
[65]
J. L. Pomerantz and D. Baltimore, “Two pathways to NF-κB,” Molecular Cell, vol. 10, no. 4, pp. 693–695, 2002.
[66]
Y. Yamamoto, U. N. Verma, S. Prajapati, K. Youn-Tae, and R. B. Gaynor, “Histone H3 phosphorylation by ikk-α is critical for cytokine-induced gene expression,” Nature, vol. 423, no. 6940, pp. 655–659, 2003.
[67]
V. Anest, J. L. Hanson, P. C. Cogswell, K. A. Steinbrecher, B. D. Strahl, and A. S. Baldwin, “A nucleosomal function for IκB kinase-α in NF-κB-dependent gene expression,” Nature, vol. 423, no. 6940, pp. 659–663, 2003.
[68]
A. K. Sil, S. Maeda, Y. Sono, D. B. Roop, and M. Karin, “IκB kinase-α acts in the epidermis to control skeletal and craniofacial morphogenesis,” Nature, vol. 428, no. 6983, pp. 660–664, 2004.
[69]
R. Gareus, M. Huth, B. Breiden et al., “Normal epidermal differentiation but impaired skin-barrier formation upon keratinocyte-restricted IKK1 ablation,” Nature Cell Biology, vol. 9, no. 4, pp. 461–469, 2007.
[70]
J. M. Dahlman, N. Bakkar, W. He, and D. C. Guttridge, “NF-κB functions in stromal fibroblasts to regulate early postnatal muscle development,” Journal of Biological Chemistry, vol. 285, no. 8, pp. 5479–5487, 2010.
[71]
N. Bakkar, J. Wang, K. J. Ladner et al., “IKK/NF-κB regulates skeletal myogenesis via a signaling switch to inhibit differentiation and promote mitochondrial biogenesis,” Journal of Cell Biology, vol. 180, no. 4, pp. 787–802, 2008.
[72]
Y. Xue, X. Wang, Z. Li, N. Gotoh, D. Chapman, and E. Y. Skolnik, “Mesodermal patterning defect in mice lacking the Ste20 NCK interacting kinase (NIK),” Development, vol. 128, no. 9, pp. 1559–1572, 2001.
[73]
N. S. Soysa, N. Alles, D. Weih et al., “The pivotal role of the alternative NF-κB pathway in maintenance of basal bone homeostasis and osteoclastogenesis,” Journal of Bone and Mineral Research, vol. 25, no. 4, pp. 809–818, 2010.
[74]
M. Mogi, T. Kondo, Y. Mizuno, and T. Nagatsu, “p53 protein, interferon-γ, and NF-κB levels are elevated in the parkinsonian brain,” Neuroscience Letters, vol. 414, no. 1, pp. 94–97, 2007.
[75]
S. Hunot, B. Brugg, D. Ricard et al., “Nuclear translocation of NF-κb is increased in dopaminergic neurons of patients with Parkinson disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 14, pp. 7531–7536, 1997.
[76]
J. P. Cao, H. J. Wang, J. K. Yu, H. M. Liu, and D. S. Gao, “The involvement of NF-κB p65/p52 in the effects of GDNF on DA neurons in early PD rats,” Brain Research Bulletin, vol. 76, no. 5, pp. 505–511, 2008.
[77]
M. J. May, F. D'Acquisto, L. A. Madge, J. Glockner, J. S. Pober, and S. Ghosh, “Selective inhibition of NF-κB activation by a peptide that blocks the interaction of NEMO with the IκB kinase complex,” Science, vol. 289, no. 5484, pp. 1550–1554, 2000.
[78]
P. Di Meglio, A. Ianaro, and S. Ghosh, “Amelioration of acute inflammation by systemic administration of a cell-permeable peptide inhibitor of NF-κB activation,” Arthritis and Rheumatism, vol. 52, no. 3, pp. 951–958, 2005.
[79]
E. Jimi, K. Aoki, H. Saito et al., “Selective inhibition of NF-κB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo,” Nature Medicine, vol. 10, no. 6, pp. 617–624, 2004.
[80]
S. Dai, T. Hirayama, S. Abbas, and Y. Abu-Amer, “The IκB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis,” Journal of Biological Chemistry, vol. 279, no. 36, pp. 37219–37222, 2004.
[81]
S. H. Davé, J. S. Tilstra, K. Matsuoka et al., “Amelioration of chronic murine colitis by peptide-mediated transduction of the IκB kinase inhibitor NEMO binding domain peptide,” Journal of Immunology, vol. 179, no. 11, pp. 7852–7859, 2007.
[82]
A. Desai, N. Singh, and R. Raghubir, “Neuroprotective potential of the NF-[kappa]B inhibitor peptide IKK-NBD in cerebral ischemia-reperfusion injury,” Neurochemistry International, vol. 57, no. 8, pp. 876–883, 2010.
[83]
G. Grassia, et al., “The I{kappa}B kinase inhibitor nuclear factor-{kappa}B essential modulator-binding domain peptide for inhibition of balloon injury-induced neointimal formation,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 12, pp. 2458–2466, 2010.
[84]
N. C. Moss, W. E. Stansfield, M. S. Willis, R. H. Tang, and C. H. Selzman, “IKKβ inhibition attenuates myocardial injury and dysfunction following acute ischemia-reperfusion injury,” American Journal of Physiology, vol. 293, no. 4, pp. H2248–H2253, 2007.
[85]
F. Zhang, L. Qian, P. M. Flood, J. S. Shi, J. S. Hong, and H. M. Gao, “Inhibition of IκB kinase-β protects dopamine neurons against lipopolysaccharide-induced neurotoxicity,” Journal of Pharmacology and Experimental Therapeutics, vol. 333, no. 3, pp. 822–833, 2010.
[86]
K. Ziegelbauer, F. Gantner, N. W. Lukacs et al., “A selective novel low-molecular-weight inhibitor of IκB kinase-β (IKK-β) prevents pulmonary inflammation and shows broad anti-inflammatory activity,” British Journal of Pharmacology, vol. 145, no. 2, pp. 178–192, 2005.
[87]
T. Hideshima, D. Chauhan, P. Richardson et al., “NF-κB as a therapeutic target in multiple myeloma,” Journal of Biological Chemistry, vol. 277, no. 19, pp. 16639–16647, 2002.
[88]
P. L. Podolin, J. F. Callahan, B. J. Bolognese et al., “Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IκB kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell proliferation,” Journal of Pharmacology and Experimental Therapeutics, vol. 312, no. 1, pp. 373–381, 2005.
[89]
M. J. O'Shaughnessy, C. Vogtenhuber, K. Sun et al., “Ex vivo inhibition of NF-κB signaling in alloreactive T-cells prevents graft-versus-host disease,” American Journal of Transplantation, vol. 9, no. 3, pp. 452–462, 2009.
[90]
T. Hideshima, T. Hayashi, D. Chauhan, M. Akiyama, P. Richardson, and K. Anderson, “Biologic sequelae of c-Jun NH-terminal kinase (JNK) activation in multiple myeloma cell lines,” Oncogene, vol. 22, no. 54, pp. 8797–8801, 2003.
[91]
J. Yang, et al., “Conditional ablation of Ikkb inhibits melanoma tumor development in mice,” The Journal of Clinical Investigation, vol. 120, no. 7, pp. 2563–2574, 2010.
[92]
M. Sch？n, B. G. Wienrich, S. Kneitz et al., “KINK-1, a novel small-molecule inhibitor of IKKβ, and the susceptibility of melanoma cells to antitumoral treatment,” Journal of the National Cancer Institute, vol. 100, no. 12, pp. 862–875, 2008.
[93]
K. Amschler, M. P. Sch？n, N. Pletz, K. Wallbrecht, L. Erpenbeck, and M. Sch？n, “NF-κB inhibition through proteasome inhibition or ikkβ blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways,” Journal of Investigative Dermatology, vol. 130, no. 4, pp. 1073–1086, 2010.
[94]
A. Yemelyanov, A. Gasparian, P. Lindholm et al., “Effects of IKK inhibitor PS1145 on NF-κB function, proliferation, apoptosis and invasion activity in prostate carcinoma cells,” Oncogene, vol. 25, no. 3, pp. 387–398, 2006.
[95]
K. W. Moore, R. De Waal Malefyt, R. L. Coffman, and A. O'Garra, “Interleukin-10 and the interleukin-10 receptor,” Annual Review of Immunology, vol. 19, pp. 683–765, 2001.
[96]
K. Strle, J. H. Zhou, W. H. Shen et al., “Interleukin-10 in the brain,” Critical Reviews in Immunology, vol. 21, no. 5, pp. 427–449, 2001.
[97]
Y. Zhu, G. Y. Yang, B. Ahlemeyer et al., “Transforming growth factor-β1 increases bad phosphorylation and protects neurons against damage,” Journal of Neuroscience, vol. 22, no. 10, pp. 3898–3909, 2002.
[98]
M. Szczepanik, M. Tutaj, K. Bryniarski, and B. N. Dittel, “Epicutaneously induced TGF-β-dependent tolerance inhibits experimental autoimmune encephalomyelitis,” Journal of Neuroimmunology, vol. 164, no. 1-2, pp. 105–114, 2005.
[99]
W. Zhang, J. S. Hong, H. C. Kim, W. Zhang, and M. L. Block, “Morphinan neuroprotection: new insight into the therapy of neurodegeneration,” Critical Reviews in Neurobiology, vol. 16, no. 4, pp. 271–302, 2004.
[100]
L. Qian, et al., “NADPH oxidase inhibitor DPI is neuroprotective at femtomolar concentrations through inhibition of microglia over-activation,” Parkinsonism and Related Disorders, vol. 13, supplement 3, pp. S316–S320, 2007.
[101]
L. Qian, P. M. Flood, and J. S. Hong, “Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy,” Journal of Neural Transmission, vol. 117, no. 8, pp. 971–979, 2010.
[102]
S. Yang, D. Zhang, Z. Yang et al., “Curcumin protects dopaminergic neuron against LPS induced neurotoxicity in primary rat neuron/glia culture,” Neurochemical Research, vol. 33, no. 10, pp. 2044–2053, 2008.
[103]
L. Qian, H. -M. Wu, S. -H. Chen et al., “β2-adrenergic receptor activation prevents rodent dopaminergic neurotoxicity by inhibiting microglia via a novel signaling pathway,” Journal of Immunology, vol. 186, no. 7, pp. 4443–4454, 2011.
[104]
A. Ghosh, A. Roy, X. Liu et al., “Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 47, pp. 18754–18759, 2007.
[105]
F. Zhang, L. Qian, P. M. Flood, J. S. Shi, J. S. Hong, and H. M. Gao, “Inhibition of IκB kinase-β protects dopamine neurons against lipopolysaccharide-induced neurotoxicity,” Journal of Pharmacology and Experimental Therapeutics, vol. 333, no. 3, pp. 822–833, 2010.
